Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Pilot Study to Evaluate the Safety and Efficacy of Subcutaneously Administered ELX-02 in Patients With Alport Syndrome With Col4A5 and Col4A3/4 Nonsense Mutation

NCT05448755 is registered in ClinicalTrials.gov with Eloxx Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05448755
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05448755 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Pilot Study to Evaluate the Safety and Efficacy of Subcutaneously Administered ELX-02 in Patients With Alport Syndrome With Col4A5 and Col4A3/4 Nonsense Mutation
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 28, 2022
Completion date
September 11, 2023
Enrollment
3 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alport syndrome